Clinical Trials › NCT03109288
RecruitingPhase 1
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
Sponsored by National Institute of Allergy and Infectious Diseases (NIAID)
Interested in joining? Eligibility criteria and contact info are on ClinicalTrials.gov.
View on ClinicalTrials.gov 250
Target enrollment
1
U.S. states
Aug 2017
Start date
Jan 2029
Expected completion
Interventions / Treatments
CilostazolLeucovorinPirfenidoneDantrolenePioglitazone
Conditions studied
Multiple Sclerosis
Where this trial is running (1 site)
Maryland1 site
Bethesda
MS centers in Maryland
Compare treatment centers near a trial site by center type, providers and trials.
View Maryland centersMore Phase 1 trials
Browse all Phase 1 MS trialsThe app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.